| Rank |
Status |
Study |
| 1 |
Recruiting
|
Microvascular Blood Flow in Sickle Cell Anemia
| Conditions: |
Sickle Cell Disease; Sickle Cell Anemia |
| Interventions: |
Drug: regadenoson infusion with contrast-enhanced ultrasound; Procedure: contrast-enhanced ultrasound |
| Outcome Measures: |
Microvascular Blood Flow in Sickle Cell Anemia with Regadenoson Use; Microvascular Blood Flow in Sickle Cell Anemia with Hydroxyurea Use; Changes in Microvascular Blood Flow in Subjects with Sickle Cell Anemia During a Pain Crisis; Microvascular Blood Flow in Sickle Cell Anemia Subjects Versus Control Subjects |
|
| 2 |
Recruiting
|
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
| Conditions: |
Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myelomonocytic Leukemia (M4); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Fanconi Anemia; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Secondary Myelodysplastic Syndromes; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies |
| Intervention: |
Other: laboratory biomarker analysis |
| Outcome Measures: |
Identification of children at high risk of having Fanconi anemia; Identification of Fanconi anemia patients |
|
| 3 |
Recruiting
|
Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
| Conditions: |
Congenital Hemolytic Anemia; Diamond-Blackfan Anemia |
| Interventions: |
Procedure: Radiotherapy; Drug: Alemtuzumab (Campath ); Drug: Sirolimus (Rapamune ) |
| Outcome Measure: |
Rate of engraftment |
|
| 4 |
Recruiting
|
Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
| Conditions: |
Severe Aplastic Anemia; Very Severe Aplastic Anemia; Moderate Aplastic Anemia |
| Intervention: |
Drug: Eltrombopag |
| Outcome Measures: |
Platelet Count Response; Platelet count twice baseline.; Hematology labs; Number of patients with AE to measure toxicity, using NCI CTCAE; Characterization of the PK profile of eltrombopag in patients with moderate to very severe aplastic anemia. Evaluated with AUC, Cmax, Cmin, tmax. |
|
| 5 |
Recruiting
|
Eltrombopag for Moderate Aplastic Anemia
| Conditions: |
Eltrombopag; Aplastic Anemia; Aplastic Anemia Treatment; Moderate Aplastic Anemia; Moderate Aplastic Anemia Treatment |
| Intervention: |
Drug: Eltrombopag |
| Outcome Measures: |
The portion of drug responders as defined by changes in the platelet count and/or platelet transfusion requirements or hemoglobin and/or PRBC transfusion requirements and the toxicity profile as measured using the CTCAE criteria.; Incidence of bleeding, changes in serum thrombopoietin level, and health related quality of life (as measured by the Medical Outcomes Study 36-Item Short Form General Health Survey, version 2 [SF36v2] Quality-Metric) measured at 16 weeks. |
|
| 6 |
Not yet recruiting
|
Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria
| Condition: |
Anaemia |
| Interventions: |
Drug: artesunate; Drug: quinine |
| Outcome Measure: |
Late onset Anaemia |
|
| 7 |
Recruiting
|
Therapeutic Use of the Amino Acid, Leucine in the Treatment of Transfusion - Dependent Diamond Blackfan Anemia Patients
| Conditions: |
Diamond Blackfan Anemia; Blackfan Diamond Syndrome; DBA; Congenital Hypoplastic Anemia; Pure Red Cell Aplasia |
| Intervention: |
Drug: leucine |
| Outcome Measures: |
Response to Leucine in Transfusion dependent patients with Diamond Blackfan Anemia; Side effects of leucine in transfusion-dependent DBA patients |
|
| 8 |
Not yet recruiting
|
The Purpose of the Study is to Examine Whether Iron Deficiency Anemia is Associated With Increased Production of Thrombin and Whether Correction of Anemia by Providing Iron Intravenously Causes a Significant Reduction in Production of Thrombin.
| Condition: |
Iron-Deficiency Anemias, |
| Intervention: |
|
| Outcome Measure: |
thrombin generation levels |
|
| 9 |
Recruiting
|
Mechanisms Accounting for Unexplained Anemia in the Elderly
| Conditions: |
Normal Aging; Anemia |
| Intervention: |
Procedure: Biotin RBC survival |
| Outcome Measures: |
Red blood cell survival in anemia and control subjects.; Inflammatory marker, red cell metabolic alternating, white blood cell mitochondrial DNA changes in anemia patients. |
|
| 10 |
Recruiting
|
IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia
| Conditions: |
Anemia; Colorectal Neoplasm |
| Interventions: |
Drug: Ferric carboxymaltose; Drug: Ferrous Sulphate |
| Outcome Measures: |
To determine if the use of intravenous ferric carboxymaltose can reduce the need for allogeneic blood transfusion compare to oral ferrous sulphate in patients with colorectal adenocarcinoma related Anaemia; To determine differences in hemoglobin and hematinic markers between the groups.; To determine differences in hepcidin levels in relation to blood profile changes in participants in the intravenous group.; To determine differences in colonic mucosal expression of iron transport proteins, C-myc and NKD1 between the groups; To determine differences in postoperative outcomes between the groups.; To determine differences in anemia symptomatology response between groups. |
|
| 11 |
Recruiting
|
Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.
| Conditions: |
Anemia; Iron Deficiency |
| Intervention: |
Drug: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid |
| Outcome Measures: |
Red blood cell (RBC) units transfused; Percentage of patients without any RBC transfusions; Combined allogeneic transfusions (RBC, FFP( fresh frozen plasma), platelets); Length of stay in the intensive care unit (ICU); Duration of mechanical ventilation; Acute kidney failure; Major Adverse Cardiac and Cerebrovascular Events (MACCE); New atrial fibrillation; Infections; Thrombotic and thromboembolic complications (90 days); Length of stay (LOS) in the hospital; Length of hospital stay (in comparison to median LOS published for relevant Swiss-DRGs); In hospital mortality; 30 day and 90-day mortality; Costs (for blood products and pharmaceutical products related to transfusion and anemia management); Perioperative Hb concentrations; Calculated RBC and blood loss; Comparison of the treatment and placebo groups with the natural comparison group; Safety and tolerance of administered study drug and placebo |
|
| 12 |
Unknown †
|
A Functional Food for the Prevention of Iron-deficiency Anemia
| Condition: |
Anemia |
| Interventions: |
Other: Control bread; Other: Teff Bread |
| Outcome Measures: |
To develop Teff bread that is rich in iron (per slice).; To establish whether iron from Teff is bioavailable.; To conclude whether daily Teff consumption prevents iron-deficiency anemia in pregnancy.; To use a range of different biomarkers to determine iron status.; To compare dietary intakes of iron and iron status between the Teff/control group. |
|
| 13 |
Not yet recruiting
|
Treatment of Iron Deficiency Anemia With Pregnancy
| Condition: |
Iron Deficiency Anemia of Pregnancy |
| Interventions: |
Drug: amino acid chelated iron; Drug: iron salt (ferrous fumarate) |
| Outcome Measures: |
change in hemoglobin level; the occurence of side effects (abdominal colics, constipation, or metallic taste); change in serum ferritin level |
|
| 14 |
Recruiting
|
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
| Condition: |
Fanconi Anemia |
| Interventions: |
Biological: anti-thymocyte globulin; Biological: filgrastim; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methylprednisolone; Biological: Hematopoietic stem cell transplantation |
| Outcome Measures: |
Percent of Graft Failure; Incidence of Acute and Chronic Graft-Versus-Host Disease; Incidence of Relapse; Incidence of Major Infections; Transplant-Related Toxicity; Overall Survival; Incidence of Chronic Graft-Versus-Host Disease |
|
| 15 |
Unknown †
|
Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy
| Conditions: |
Restless Leg Syndrome; Iron Deficiency Anemia |
| Intervention: |
Drug: ferric carboxymaltose |
| Outcome Measures: |
Primary endpoint: = 50% reduction of RLS symptoms as measured by International Restless Legs Study Group (IRLSS); Reduction of Periodic Limb Movements in Sleep (PLMS) ≥50% as measured with actimetry; Improvement of sleep according to the Pittsburgh Sleep Quality Questionnaire (PSQI); Improvement of sleepiness using Epworth Sleepiness Scale (ESS); Improvement of fatigue using Fatigue Severity Scale (FSS); Safety of ferric carboxymaltose during pregnancy in the 3rd trimester; Parameters of the newborn baby (apgar, umbilical artery pH, weight, mode of delivery) |
|
| 16 |
Recruiting
|
Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia
| Condition: |
Sickle Cell Anemia |
| Intervention: |
|
| Outcome Measures: |
VO2 max on cardiopulmonary exercise test; Quality of life questionnaires; Echocardiogram; Dual Energy X-ray Absorbtiometry; Pulmonary Function Test |
|
| 17 |
Recruiting
|
Quercetin in Children With Fanconi Anemia; a Pilot Study
| Condition: |
Fanconi Anemia |
| Intervention: |
Drug: Quercetin (dietary supplement) |
| Outcome Measures: |
Measure the ability to administer twice daily oral quercetin therapy in patients with Fanconi Anemia (FA).; Measure safety of oral quercetin therapy in patients with FA; To measure pharmacokinetics (PK) of oral quercetin therapy in patients with FA; To measure the impact of quercetin therapy on reduction of Reactive Oxygen Species (ROS).; Number of participants with improved hematopoiesis.; Measure the preservation of hematopoietic stem cell reserve in patients with FA; Number of participants with changes in insulin sensitivity/glucose tolerance. |
|
| 18 |
Recruiting
|
The Safety and Effectiveness of Jobelyn in Pre-operative Management of Anaemia in Gynaecological Patients
| Condition: |
Anemia |
| Interventions: |
Dietary Supplement: Jobelyn; Drug: Ferrous Sulphate + Folic Acid |
| Outcome Measures: |
Anaemia; morbidity |
|
| 19 |
Recruiting
|
Alemtuzumab to Treat Severe Aplastic Anemia
| Conditions: |
Relapsed or Refractory Severe Aplastic Anemia; Severe Aplastic Anemia |
| Intervention: |
Drug: Alemtuzumab (Campath ) |
| Outcome Measures: |
Response rate at six months, defined as no longer satisfying blood count criteria for SAA.; Relapse, robustness of the hematopoietic recovery at three and six months, three months responses, survival, and clonal evolution to myelodysplasia and acute leukemia. |
|
| 20 |
Recruiting
|
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
| Conditions: |
Anemia; Chronic Kidney Disease; Kidney Disease |
| Interventions: |
Drug: darbepoetin alfa QW; Drug: darbepoetin alfa Q2W |
| Outcome Measures: |
To test if the proportion of subjects achieving a Hb value >/= 10.0 g/dL at any time point after the first dose during the study is greater than 0.8 when administered de novo darbepoetin alfa QW for treatment of anemia in pediatric CKD subjects receiving; To test if the proportion of subjects achieving a Hb value >/= 10.0 g/dL at any time point after the first dose during the study is greater than 0.8 when administered de novo darbepoetin alfa Q2W for treatment of anemia in pediatric CKD subjects receivin; To assess the health-related quality of life in pediatric CKD subjects >/= 2 years old over the duration of the study in the QW and Q2W arms; To obtain pharmacokinetic (PK) data in subjects < 6 years of age; To assess the safety and tolerability of darbepoetin alfa administered QW and Q2W; To estimate Hb values over the duration of the study in the QW and Q2W arms; To estimate doses over the duration of the study in the QW and Q2W arms |
|
